Literature DB >> 19074898

Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.

David A Solomon1, Jung-Sik Kim, Julia C Cronin, Zita Sibenaller, Timothy Ryken, Steven A Rosenberg, Habtom Ressom, Walter Jean, Darell Bigner, Hai Yan, Yardena Samuels, Todd Waldman.   

Abstract

An additional tumor suppressor gene on chromosome 9p telomeric to the CDKN2A/B locus has long been postulated to exist. Using Affymetrix 250K single nucleotide polymorphism arrays to screen for copy number changes in glioblastoma multiforme (GBM), we detected a high frequency of deletions of the PTPRD gene, which encodes a receptor protein tyrosine phosphatase at chromosome 9p23-24.1. Missense and nonsense mutations of PTPRD were identified in a subset of the samples lacking deletions, including an inherited mutation with somatic loss of the wild-type allele. We then sequenced the gene in melanoma and identified 10 somatic mutations in 7 of 57 tumors (12%). Reconstitution of PTPRD expression in GBM and melanoma cells harboring deletions or mutations led to growth suppression and apoptosis that was alleviated by both the somatic and constitutional mutations. These data implicate PTPRD in the pathogenesis of tumors of neuroectodermal origin and, when taken together with other recent reports of PTPRD mutations in adenocarcinoma of the colon and lung, suggest that PTPRD may be one of a select group of tumor suppressor genes that are inactivated in a wide range of common human tumor types.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074898      PMCID: PMC2760967          DOI: 10.1158/0008-5472.CAN-08-3272

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Receptor tyrosine phosphatase-delta is a homophilic, neurite-promoting cell adhesion molecular for CNS neurons.

Authors:  J Wang; J L Bixby
Journal:  Mol Cell Neurosci       Date:  1999 Oct-Nov       Impact factor: 4.314

Review 2.  Cell adhesion in development: a complex signaling network.

Authors:  Jean Paul Thiery
Journal:  Curr Opin Genet Dev       Date:  2003-08       Impact factor: 5.578

3.  CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin.

Authors:  A L Cook; P M Pollock; J Welch; M D Walsh; R V Bowman; K C Baumann; N K Hayward; J H Leonard
Journal:  Int J Cancer       Date:  2001-08-01       Impact factor: 7.396

4.  Cell-cell adhesion mediated by a receptor-like protein tyrosine phosphatase.

Authors:  M F Gebbink; G C Zondag; R W Wubbolts; R L Beijersbergen; I van Etten; W H Moolenaar
Journal:  J Biol Chem       Date:  1993-08-05       Impact factor: 5.157

5.  Molecular characterization of the human transmembrane protein-tyrosine phosphatase delta. Evidence for tissue-specific expression of alternative human transmembrane protein-tyrosine phosphatase delta isoforms.

Authors:  R Pulido; N X Krueger; C Serra-Pagès; H Saito; M Streuli
Journal:  J Biol Chem       Date:  1995-03-24       Impact factor: 5.157

6.  Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.

Authors:  P M Pollock; J Welch; N K Hayward
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

7.  Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme.

Authors:  David A Solomon; Jung-Sik Kim; Sultan Jenkins; Habtom Ressom; Michael Huang; Nicholas Coppa; Lauren Mabanta; Darell Bigner; Hai Yan; Walter Jean; Todd Waldman
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p.

Authors:  K Ueki; M P Rubio; V Ramesh; K M Correa; J L Rutter; A von Deimling; A J Buckler; J F Gusella; D N Louis
Journal:  Hum Mol Genet       Date:  1994-10       Impact factor: 6.150

9.  Mutational analysis of the tyrosine phosphatome in colorectal cancers.

Authors:  Zhenghe Wang; Dong Shen; D Williams Parsons; Alberto Bardelli; Jason Sager; Steve Szabo; Janine Ptak; Natalie Silliman; Brock A Peters; Michiel S van der Heijden; Giovanni Parmigiani; Hai Yan; Tian-Li Wang; Greg Riggins; Steven M Powell; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-05-21       Impact factor: 47.728

10.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

Authors:  C Li; W H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  69 in total

Review 1.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 2.  Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.

Authors:  Kurt M Kroeger; A K M Ghulam Muhammad; Gregory J Baker; Hikmat Assi; Mia K Wibowo; Weidong Xiong; Kader Yagiz; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

3.  Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.

Authors:  Barbara S Paugh; Chunxu Qu; Chris Jones; Zhaoli Liu; Martyna Adamowicz-Brice; Junyuan Zhang; Dorine A Bax; Beth Coyle; Jennifer Barrow; Darren Hargrave; James Lowe; Amar Gajjar; Wei Zhao; Alberto Broniscer; David W Ellison; Richard G Grundy; Suzanne J Baker
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

4.  Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma.

Authors:  Xiaomu Wei; Todd D Prickett; Cristina G Viloria; Alfredo Molinolo; Jimmy C Lin; Isabel Cardenas-Navia; Pedro Cruz; Steven A Rosenberg; Michael A Davies; Jeffrey E Gershenwald; Carlos López-Otín; Yardena Samuels
Journal:  Mol Cancer Res       Date:  2010-10-13       Impact factor: 5.852

5.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Authors:  Karine Michaud; David A Solomon; Eric Oermann; Jung-Sik Kim; Wei-Zhu Zhong; Michael D Prados; Tomoko Ozawa; C David James; Todd Waldman
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

6.  Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays.

Authors:  Inês Crespo; Ana Luísa Vital; Ana Belen Nieto; Olinda Rebelo; Hermínio Tão; Maria Celeste Lopes; Catarina Resende Oliveira; Pim J French; Alberto Orfao; María Dolores Tabernero
Journal:  J Mol Diagn       Date:  2011-08-30       Impact factor: 5.568

7.  Sample type bias in the analysis of cancer genomes.

Authors:  David A Solomon; Jung-Sik Kim; Habtom W Ressom; Zita Sibenaller; Timothy Ryken; Walter Jean; Darell Bigner; Hai Yan; Todd Waldman
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

Review 8.  PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.

Authors:  George R Uhl; Maria J Martinez
Journal:  Ann N Y Acad Sci       Date:  2019-01-15       Impact factor: 5.691

Review 9.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

10.  Distinct high-profile methylated genes in colorectal cancer.

Authors:  Pooneh Mokarram; Krishan Kumar; Hassan Brim; Fakhraddin Naghibalhossaini; Mehdi Saberi-firoozi; Mehdi Nouraie; Robert Green; Ed Lee; Duane T Smoot; Hassan Ashktorab
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.